Daniel J. Siegwart

Daniel J. Siegwart holds the W. Ray Wallace Distinguished Chair in Molecular Oncology Research and serves as Professor at the University of Texas Southwestern Medical Center. He maintains dual appointments in the Department of Biomedical Engineering and Department of Biochemistry, and is affiliated with the Simmons Comprehensive Cancer Center. Dr. Siegwart directs both the Program in Genetic Drug Engineering and the Drug Delivery Program in Biomedical Engineering, while also serving as Co-Director of the Chemistry and Cancer Program.

Dr. Siegwart's research focuses on developing advanced lipid and polymer-based systems with precise control over structure and responsiveness for applications in drug delivery, imaging, genetic diseases, and cancer. His work spans nano-based drugs, personalized medicine, and cancer immunology, with particular emphasis on creating targeted delivery systems for nucleic acid therapeutics. His laboratory pioneers innovations in lipid nanoparticle technology, selective organ targeting (SORT) systems, and novel approaches to overcome delivery barriers for genetic medicines.

Analysis of Dr. Siegwart's recent publications reveals a strong focus on advancing lipid nanoparticle technology for organ-specific delivery of nucleic acids. His research group has made significant contributions to understanding structure-activity relationships of ionizable lipids, developing multi-organ targeting strategies, and creating solutions for repeated administration of mRNA therapeutics. Current work emphasizes expanding delivery capabilities beyond the liver to target lungs, spleen, skeletal muscle, and skin for treating genetic diseases and cancer.

• National Academy of Inventors (NAI) Fellow (2024)
• National Academy of Medicine (NAM) Emerging Leaders in Health and Medicine (ELHM) Scholar (2024)
• Controlled Release Society (CRS) College of Fellows (2023)
• American Institute for Medical and Biological Engineering (AIMBE) College of Fellows (2022)
• Howard Hughes Medical Institute (HHMI) Gilliam Fellowship for Advanced Study (2021)

Dr. Siegwart has secured significant research funding including the American Cancer Society Research Scholar award, CPRIT Scholar Award, and NIH funding. He has co-founded multiple biotechnology companies including Signify Bio, Jumble Therapeutics, and ReCode Therapeutics, translating his academic research into clinical applications. His laboratory maintains active collaborations with leading institutions and pharmaceutical companies to advance nucleic acid delivery technologies.

The Siegwart laboratory operates as a multidisciplinary research team at the intersection of chemistry, materials science, and biomedical engineering. The group maintains state-of-the-art facilities for nanoparticle formulation, characterization, and in vivo testing, with particular expertise in lipid chemistry, polymer synthesis, and nucleic acid delivery. Current research directions include developing next-generation delivery systems for CRISPR-based gene editing, creating tissue-specific mRNA vaccines, and engineering novel approaches to treat genetic disorders and cancer.